Anita Turk, MD, details her biggest takeaways from the 2025 ASCO Annual Meeting in gastrointestinal cancers. Anita Turk, MD, medical oncologist at IU Health, discusses her biggest takeaways in the ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

June brought genitourinary cancer updates, and CURE is sharing the latest in kidney cancer treatment, as well as FDA ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Bristol-Myers Squibb Company (NYSE:BMY) is the third biopharmaceutical company on the list of the 10 undervalued blue chip ...

Dr. Michael Serzan emphasizes the importance of clinical trial participation for patients with kidney cancer.

The FDA recently granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the ...